214 related articles for article (PubMed ID: 18719096)
1. Brk is coamplified with ErbB2 to promote proliferation in breast cancer.
Xiang B; Chatti K; Qiu H; Lakshmi B; Krasnitz A; Hicks J; Yu M; Miller WT; Muthuswamy SK
Proc Natl Acad Sci U S A; 2008 Aug; 105(34):12463-8. PubMed ID: 18719096
[TBL] [Abstract][Full Text] [Related]
2. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
Lofgren KA; Ostrander JH; Housa D; Hubbard GK; Locatelli A; Bliss RL; Schwertfeger KL; Lange CA
Breast Cancer Res; 2011 Sep; 13(5):R89. PubMed ID: 21923922
[TBL] [Abstract][Full Text] [Related]
3. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer.
Allen-Petersen BL; Carter CJ; Ohm AM; Reyland ME
Oncogene; 2014 Mar; 33(10):1306-15. PubMed ID: 23474764
[TBL] [Abstract][Full Text] [Related]
5. Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.
Mizuguchi Y; Specht S; Isse K; Sasatomi E; Lunz JG; Takizawa T; Demetris AJ
J Hepatol; 2015 Aug; 63(2):399-407. PubMed ID: 25770659
[TBL] [Abstract][Full Text] [Related]
6. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
Ai M; Liang K; Lu Y; Qiu S; Fan Z
Cancer Biol Ther; 2013 Mar; 14(3):237-45. PubMed ID: 23291984
[TBL] [Abstract][Full Text] [Related]
7. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Peng M; Ball-Kell SM; Tyner AL
Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
[TBL] [Abstract][Full Text] [Related]
8. Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion.
Shen CH; Chen HY; Lin MS; Li FY; Chang CC; Kuo ML; Settleman J; Chen RH
Cancer Res; 2008 Oct; 68(19):7779-87. PubMed ID: 18829532
[TBL] [Abstract][Full Text] [Related]
9. Tracing the footprints of the breast cancer oncogene BRK - Past till present.
Goel RK; Lukong KE
Biochim Biophys Acta; 2015 Aug; 1856(1):39-54. PubMed ID: 25999240
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
11. Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6.
Weaver AM; Silva CM
Breast Cancer Res; 2007; 9(6):R79. PubMed ID: 17997837
[TBL] [Abstract][Full Text] [Related]
12. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.
Muthuswamy SK; Siegel PM; Dankort DL; Webster MA; Muller WJ
Mol Cell Biol; 1994 Jan; 14(1):735-43. PubMed ID: 7903421
[TBL] [Abstract][Full Text] [Related]
13. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
14. Putting the BRK on breast cancer: From molecular target to therapeutics.
Ang HL; Yuan Y; Lai X; Tan TZ; Wang L; Huang BB; Pandey V; Huang RY; Lobie PE; Goh BC; Sethi G; Yap CT; Chan CW; Lee SC; Kumar AP
Theranostics; 2021; 11(3):1115-1128. PubMed ID: 33391524
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
16. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells.
Neve RM; Sutterlüty H; Pullen N; Lane HA; Daly JM; Krek W; Hynes NE
Oncogene; 2000 Mar; 19(13):1647-56. PubMed ID: 10763821
[TBL] [Abstract][Full Text] [Related]
17. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
18. β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.
Schade B; Lesurf R; Sanguin-Gendreau V; Bui T; Deblois G; O'Toole SA; Millar EK; Zardawi SJ; Lopez-Knowles E; Sutherland RL; Giguère V; Kahn M; Hallett M; Muller WJ
Cancer Res; 2013 Jul; 73(14):4474-87. PubMed ID: 23720052
[TBL] [Abstract][Full Text] [Related]
19. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
[TBL] [Abstract][Full Text] [Related]
20. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.
Li X; Lu Y; Liang K; Hsu JM; Albarracin C; Mills GB; Hung MC; Fan Z
Oncogene; 2012 Oct; 31(40):4372-83. PubMed ID: 22231447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]